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1. Introduction 
Chlamydia trachomatis infection is a major and increasing public health problem worldwide 
and is currently the main cause of sexually-transmitted infections (STI). The incidence of this 
infection is highest in young women and is especially important in this population group 
due to the potential consequences in the female reproductive tract, such as pelvic 
inflammatory disease, tubal damage, and infertility. During pregnancy, C. trachomatis 
infection has been associated with adverse outcomes, including spontaneous abortion, 
ectopic pregnancy, premature rupture of membranes, preterm birth.  Moreover, the 
infection can be transmitted perinatally to women’s offspring causing neonatal 
conjunctivitis, nasopharyngitis and pneumonia. 
Because of the particular characteristics of this intracellular microorganism (unique biphasic 
division cycle, slow metabolism) and its interaction with the host’s immune response, C. 
trachomatis infection may often pass unnoticed and be under-diagnosed, facilitating its 
spread, which is mainly associated with sexual risk behaviour. C. trachomatis is currently 
classified in 18 genotypes, or serovars, based on the genetic variation of the major outer 
membrane protein (MOMP). The genotypes most frequently producing genitourinary tract 
infection are genotypes D, E, F, G, H, I, J and K. In the last decade, the microbiological 
diagnosis of C. trachomatis infection has improved due to the development of nucleic acid 
amplification techniques (NAATs) and their progressive introduction in laboratories. 
Contact tracing is essential in the management of this infection to avoid reinfections. Due to 
the high and growing impact of C. trachomatis infection in public health, the main 
international agencies involved in STI surveillance (Centers for Disease Control and 
Prevention [CDC], European Centre for Disease Prevention and Control [ECDC]...) have 
proposed various prevention measures and levels of intervention to improve its control.  
This chapter discusses the transmission and epidemiological data of C. trachomatis infection 
in women of reproductive age, especially pregnant women, and the etiopathogenic 
mechanisms causing its symptoms and sequelae on fertility and pregnancy. The 
management of this infection in pregnancy will be analysed in detail, focusing on diagnosis 
and appropriate treatment, information on the possible effects of this infection, and partner 
management, which may raise particularly delicate issues. Finally, the screening strategies 
established in several countries for the population groups with the highest prevalence of 
this infection will be described and their effectiveness in controlling its spread and in 
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preventing its adverse effects on fertility, pregnancy and vertical transmission, will be 
analysed. 
2. Epidemiology 
2.1 Transmission 
Transmission of C. trachomatis infection is through direct contact between the mucous 
membranes of two individuals during sexual activity or through an infected birth canal. 
Because of the anatomical characteristics of the female genital tract, the risk of contracting an 
STI is higher in women than in men.  
As with other STI, the risk of C. trachomatis transmission is directly related to certain sexual 
activities, such as starting sexual relations at an early age, their frequency, and a recent 
change of partner, and especially to risk behaviours, such as sexual activity without 
protection or incorrect condom use, multiple sexual partners and promiscuity. Other risk 
factors are a history of contact with C. trachomatis or other STI, a previous STI, etc. Pregnant 
women are not free of these risks. 
In the last few years, the incidence of this infection has increased, partly due to a false sense 
of security created by antiviral HIV therapy in some sectors of the population, leading to 
carelessness in the use of preventive methods during sexual relations, thus facilitating STI. 
A higher risk of infection has been described in persons with a low socioeconomic position 
and in substance abusers, due to lower awareness of and compliance with preventive 
measures in these population groups. Adolescents are the group most likely to engage in 
high-risk behaviours, such us unprotected sex, especially when they are under the influence 
of drugs or alcohol. 
A major feature of the epidemiology of C. trachomatis infection is the high percentage of the 
infected population that may be asymptomatic, often for several months. While the 
percentage of asymptomatic infected men is estimated to be up to 50%, in women this 
percentage may be as high as 70-75% (18). Asymptomatic infected individuals may spread 
undiagnosed infection among the sexually active population. Consequently, to improve C. 
trachomatis infection control, in many countries screening strategies have been 
recommended in the population with the highest prevalence, in addition to treatment of 
cases and partner management to prevent reinfections.  
Transmission of C. trachomatis infection among the population can also be facilitated by the 
emergence of mutated strains, as occurred in Sweden in 2006 with the new variant of C. 
trachomatis (nvCT), which was not detected with the molecular techniques used in some 
regions due to a 377 bp deletion in the cryptic plasmid (74). The nvCT caused many false-
negative diagnoses, allowing this variant to spread to other northern European countries 
(91). Fortunately, spread beyond these countries has been limited (70). 
Another important issue is that other microorganisms causing an STI, including HIV, 
hepatitis B virus, herpes simplex viruses, Neisseria gonorrhoeae, Treponema pallidum, can be 
transmitted in the same episode as that leading to C. trachomatis infection. Moreover, in C. 
trachomatis-infected individuals, there is a greater risk of acquiring and, in the case of 
coinfection, of transmitting other STI due to the inflammatory alterations produced in 
affected genital mucous membranes (28).   
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2.2 Incidence rate   
C. trachomatis affects over 600 million people worldwide with more than 90 million new 
cases occurring globally each year (98). In the USA, more than 1.2 million new cases were 
reported in 2009, a rate of 409/100,000 people, the most frequently affected being young 
black women aged 15-24 years (22). In Europe, an incidence rate of 150/100,000 inhabitants 
has been reported, with an incidence of 1,200/100,000  among women aged between 15 and 
24 years (35). The real figures are probably higher since cases are under-reported due to the 
marked differences in national surveillance and reporting systems. Indeed, some European 
countries do not provide data, others report very low incidence rates (<1/100,000 
inhabitants), and some regions, such as Nordic countries or the UK, report incidence rates of 
>250/100,000 inhabitants. Consequently, the reported data should be interpreted with 
caution: a low rate could under estimate the real incidence if the diagnostic measures and 
reporting systems are inadequate; however an increasing rate may not reflect greater 
transmission of the infection in countries implementing screening programs that allow 
detection of asymptomatic cases. Nevertheless, the tendencies in data from several countries 
show that the reported incidence of C. trachomatis infection has increased considerably in the 
last few years (Figure 1). This increase may be due to the sum of multiple factors: the rise in 
sexual risk behaviours, decreased compliance with preventive measures, greater knowledge 
and awareness of C. trachomatis infection – leading to more frequent diagnosis –, increased 
sensitivity of diagnostic methods, and improvement in reporting systems, among other 
factors.   
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Fig. 1. Incidence rate of C. trachomatis and other sexually transmitted infections in the EU per 
100,000 inhabitants (ECDC data). (HBV: hepatitis B virus). 
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Author, country, 
study period, 
(reference) 
Samples Population 
Women 
analysed 
(prevalence) 
Factors associated 
with higher 
prevalence 
X.S. Chen et al, China 
(Fuzhou, Fujian), Jul-
Sep/02 (25) 
Cervix 
Antenatal care 
attendees (first 
prenatal visit) 
504 
(10.1%) 
Younger (18% in 25 
years), higher 
monthly income 
Pinto et al, Brazil 
(national study), Mar-
Nov/09 (67) 
Urine 
Parturient women 
15-24 years 
2071 
(9.8%) 
Younger (13% in 
<20 years), first 
sexual intercourse 
<15 years, >1 
partners/yr. 
Romoren et al, 
Bostwana 
(Gaberone), Oct/00-
Feb/01 (76) 
Cervix 
Antenatal care 
attendees 
703 
(8%) 
Younger (<20 
years), unmarried, 
<1 year in 
relationship 
Kilmarx et al, 
Thailand (Bangkok 
and Chiang Rai), Jun-
Dec/96 (51) 
Urine 
Antenatal care 
attendees (first 
prenatal visit) 
1021 
(5.7%) 
Younger (13% in 
<20 years), higher 
gestational age 
Silveira et al, USA 
(Baltimore, 
Maryland), Jul/05-
Feb/08 (RS) (85) 
Not 
provided
Parturient women 
with antenatal care 
information 
available 
2127 
(4.7%) 
Younger (12% in 
<20 years), ethnicity 
(black), single, 
smoking, NG  
during pregnancy 
Roberts et al, USA 
(Dallas, Texas), May-
Sep/09 (75) 
Cervix 
and urine
Pregnant women at 
35-37 weeks’ 
gestation 
2018 
(cervix: 4.3%)
(urine: 4.1%) 
Not provided 
Rours et al, 
The Netherlands 
(Rotterdam), Feb/03-
Jan/05 (77) 
Urine 
Pregnant women 
attending 
midwifery practice 
or antenatal clinic 
4055 
(3.9%) 
Younger (13% in 
<21 years), ethnicity 
(16% in Antillean), 
single (12%) 
McMillan et al, 
Ireland (Dublin), 
Jun/03-May/04 (60) 
Urine 
Asymptomatic 
pregnant women 
783 
(3.8%) 
Younger and single 
M.Y. Chen et al., 
Australia 
(Melbourne), Oct/06-
Jul/07 (24) 
Urine 
Pregnant women 
16-25 years 
987 
(3.2%) 
>1 sexual partner in 
the past year (12%) 
Böhm et al., Germany 
(national study), Apr-
Dec/08 (RS) (14) 
Cervix 
(group1), 
urine 
(group 2)
Asymptomatic (g1 
and 2) or 
symptomatic (g 3) 
pregnant women 
51164 (3.1%) 
g1: 31856 
(3.3%) 
g2: 18169 
(2.9%) 
g3: 1139 (2.0%)
Younger (10% in ≤20 
years) 
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Author, country, 
study period, 
(reference) 
Samples Population 
Women 
analysed 
(prevalence) 
Factors associated 
with higher 
prevalence 
Oakeshott et al, 
United Kingdom 
(south London), 
Jun/98-Jul/00 (63) 
 
Vaginal 
(self 
taken), 
urine 
Pregnant women 
<10 weeks‘ 
gestation (general 
practice and family 
planning clinic) 
1216 
(2.4%) 
Younger (9% in <25 
years, 14% in 
teenagers), ethnicity 
(9% in blacks) 
Hospital Donostia, 
Spain 
(Data not yet 
published, Oct/10-
May/11) 
Urine 
Pregnant women 
with complications 
and unselected 
parturient women 
551 
(1.5%) 
Younger (5.2% in 
<30 years) 
Abbreviations: NG: Neisseria gonorrhoeae; RS: retrospective study 
Table 1. Prevalence of C. trachomatis infection determined by nucleic acid amplification 
techniques in studies performed in pregnant women (attending antenatal services) or 
parturient women throughout the world (if not otherwise specified, prospective, cross-
sectional, observational studies). 
In the last few years, numerous epidemiological studies have aimed to determine the 
prevalence of C. trachomatis infection in pregnant women, an essential step for the design of 
appropriate infection control programs in distinct geographical regions (Table 1). The results 
of these studies are influenced by the sociodemographic characteristics of the population 
studied, such as age, setting of the population tested, and risk factors, etc., as well as by the 
type of sample and the diagnostic method used. Currently, the methods of choice in these 
studies are based on NAATs, generally indicating a prevalence of between 1 and 10%, the 
highest prevalence being found among young pregnant women and single pregnant women.  
Specifically, the prevalence in women aged less than 20-22 years was >10% in studies 
performed in countries as far apart as Botswana, Brasil, Germany, the USA and Ireland.  
3. Symptoms, etiopathogenesis, and sequelae  
The main target of C. trachomatis are columnar epithelial cells, particularly in the cervix and 
urethra, as well as in the rectum, throat, and conjunctiva; in adult women, the squamous 
epithelium of the vagina is unreceptive to infection. Most infections in women start in the 
endocervix and the main clinical manifestation in symptomatic infections is cervicitis, 
sometimes with intermenstrual or postcoital bleeding or dyspareunia. Symptoms usually 
begin 2 to 6 weeks after infection. Vaginal discharge is present in 50% and is usually mucous 
and less abundant and purulent than in Neisseria gonorrhoeae infections. Dysuria and 
pollakiuria are infrequent, but urethritis can be associated with cervicitis. In women with 
hypogastric pain, pelvic inflammatory disease (PID) should be suspected. Depending on 
sexual practices, other local symptoms (pharyngeal, rectal) may be present. Without an 
accurate and rapid diagnosis, untreated infections (symptomatic or asymptomatic), may 
spread among the sexually active population and give rise to complications and sequelae. 
The consequences of C. trachomatis infection for women’s reproductive health can be severe. 
This pathogen may spread upward from the endocervix, possibly due to binding to 
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spermatozoids or the passive transport mechanisms of the genital tract, causing 
endometritis, salpingitis or PID, which can lead to sequelae in 10-20% of patients, mainly 
infertility and ectopic pregnancy (19).  The risk of PID is increased in women with C. 
trachomatis infection who undergo uterine instrumentation, which can reactivate the bacteria 
or provoke upward spread (4). In addition, C. trachomatis can occasionally cause HLA-B27-
associated reactive arthritis, Reiter’s syndrome, perihepatitis, and Fitz-Hugh-Curtis 
syndrome. Another complication of C. trachomatis infection is its possible role as a 
carcinogenic co-factor in the development of cervical neoplasms caused by high-risk human 
papillomavirus (HPV) types (66).  
During pregnancy, these infections have been associated with premature rupture of 
membranes, premature delivery, low birth weight neonates, and miscarriage. Women can 
infect their neonates through the birth canal, causing conjunctivitis, nasopharyngitis and 
pneumonia. The risk of perinatal transmission has been estimated to be 20-50% for 
conjunctivitis (manifesting at 5-12 days after birth), frequently associated with 
nasopharyngeal infection, and 10-20% for pneumonia (at 1-3 months) (16). Postpartum 
endometritis can also be associated with C. trachomatis infection.  
3.1 Factors involved in etiopathogenesis  
Knowledge of the etiopathogenesis and mechanisms of interaction among microorganisms 
and their hosts is important to adopt the most appropriate prevention and control strategies, 
such as screening of high-risk populations, optimal screening intervals, etc., and will help in 
the development of future vaccines. Paradoxically, in some patients, the defense 
mechanisms against C. trachomatis infection – mainly the inflammatory and adaptive 
immune responses - could be harmful to tissues. Tissue lesions giving rise to sequelae could 
be of immunopathological origin rather than due to the direct action of chlamydia.  
Epithelial cells are the first defense against C. trachomatis infection. On becoming infected, 
these cells secrete chemokines and cytokines, which stimulate the cellular inflammatory 
response (leucocytes, natural killer cells, dendritic cells...). The continuous release of some of 
these cytokines (interleukin [IL]-1, IL-8...), especially during chronic or repeated infections, 
can cause direct tissue damage and scarring (17,87).  
In addition, shortly after C. trachomatis infection, an innate cellular immune response is 
produced, mediated mainly by CD4+ T cells, with production of Th1-type cytokines, such as 
tumor necrosis factor (TNF)- and interferon (INF)-, which inhibit intracellular chlamydial 
replication (39). If the infection is not eradicated and persists, or in repeat infections, 
adaptive T cell immune responses against C. trachomatis antigens can be produced, which 
could collaterally contribute to the development of inflammatory sequelae through 
autoimmune or delayed hypersensitivity mechanisms, which are still not well understood 
(17). In experimental animal models, in repeat infections, the enhanced inflammatory 
response may be mediated by cytotoxic CD8+ T cells primed against chlamydial heat shock 
protein 60 (cHSP60), producing greater tissue destruction and fibrosis than in the initial 
infection, this risk increasing with each additional reinfection (56,71). Serum and genital 
mucosal IgA and IgG antibodies to specific C. trachomatis proteins such as cHSP and to 
chlamydial elementary bodies (EBs) are usually detected during active infection in women 
(37), but their precise role in the resolution of infection remains unclear. 
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In vitro studies have revealed that the peculiar metabolic cycle of C. trachomatis can be altered 
by INF- and other inducers. In a normal cycle, the infectious but metabolically inactive 
extracellular EBs infect cells, and once inside, they differentiate to non-infectious but 
metabolically active intracellular reticulate bodies (RBs) that multiply by binary fission within 
vacuoles. In turn, these RBs reorganize back to EBs that are released to the extracellular 
medium. In the altered cycle, morphologically enlarged, aberrant, and nondividing RBs are 
found in a viable but noncultivable state (100). This mechanism may contribute to persistent C. 
trachomatis infection in humans, avoiding the immune system and inducing an 
immunopathogenic response. However, the question of whether these altered RBs appear in 
vivo and are involved in the development of sequelae remains to be elucidated.  
Other determining factors in the development of PID and sequelae may be the natural 
duration of untreated C. trachomatis infection in the host and the number of infections 
acquired. Approximately half of infections resolve spontaneously in the first year after 
initial chlamydia testing, but in some women infections may persist for several years. The 
duration of infection and the chlamydial load in repeat infections seem to be lower than in 
the first infection, suggesting the existence of some degree of partial immunity (37). 
However, repeat infections are common and are associated with a higher risk of PID and 
sequels (41). The sooner an infection is detected, the lower the microorganism’s opportunity 
to ascend the upper genital tract and the lesser the time of action of the immunopathological 
mechanisms involved in the development of sequelae.  
Only a minority of infected women develop reproductive disorders, due to differences in 
numerous factors including the type of dendritic cell, co-stimulatory molecule expression, 
the cytokine secretion pattern and hormone levels (1). Therefore, there may be a greater 
genetic predisposition linked to expression of specific C. trachomatis cell receptors, as well as 
differentiated mechanisms in the immunological response (HLA class I and II variants and 
functional polymorphisms in cytokine) that determines the result of infection in the host and 
its potential consequences (3,88).  
Although the ompA gene of C. trachomatis evolves more rapidly than the remaining genome, 
and its product (MOMP) is exposed on the surface of EBs, there is no evidence that any 
genotypic C. trachomatis variant (MOMP serovars) has a greater capacity than other variants 
to spread or avoid the immune response and produce greater clinical severity (30,92). The 
possible roles of other C. trachomatis biomarkers, such as the polymorphic outer membrane 
autotransporter family of proteins (89), type III secretion system effectors (29), and the 
putative large cytotoxin (9) are currently being studied. These biomarkers could help to 
identify strain-specific variants with distinct pathogenic characteristics. Further studies that 
analyse the phenotypic behaviour of this microorganism together with the clinical and 
epidemiological features of the population studied are required. Furthermore, new studies 
should attempt to gain greater insight into the molecular epidemiology of the strains 
involved through techniques allowing high genotypic discrimination, such as multilocus 
sequence typing (MLST), variable number tandem repeat (VNTR)...  
3.2 Main reproductive health sequelae in women 
3.2.1 PID 
PID includes several genital tract disorders among women, such as endometritis, salpingitis, 
tubo-ovarian abscess and pelvic peritonitis. For PID to occur, C. trachomatis, N. gonorrhoeae, 
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or other microorganisms must spread upward from the lower genital tract, infecting and 
causing inflammation of the uterus, fallopian tubes, and ovaries. The most frequent cause of 
PID is C. trachomatis genital infection, and studies in women with laparoscopically proven 
PID have described a prevalence of 10-60% (86). However, the risk of developing PID 
among C. trachomatis-infected women is not well known since few prospective studies have 
been performed and the number of cases included has generally been small. Despite these 
limitations, the risk seems to be high: the results of a recent randomised controlled trial 
performed in the UK that included 75 women with untreated, asymptomatic C. trachomatis 
infection found that 9.5% (95% CI 4.7%-18.3%) developed PID over 1 year (63). Although 
current data are limited, the risk of developing PID seems to be higher in the first few weeks 
of infection (41).  
The main clinical manifestation of PID is abdominal pain. However, particularly in the 
initial stages, the symptoms may be non-specific, consisting of abnormal discharge, 
intermenstrual or postcoital bleeding, fever, urinary frequency, low back pain, 
nausea/vomiting, etc., and several consultations are required to reach a diagnosis. After a 
PID – which can be symptomatic or subclinical – gynecological and reproductive sequelae 
may appear, such as infertility (15-20%), ectopic pregnancy (an increased risk of 6-10-fold ) 
and chronic pelvic pain, as a result of alterations in the cilia lining the fallopian tubes, 
destruction of ciliated cells, tubal occlusion, scarring, or adhesion formation among pelvic 
organs. However, the risk of developing sequelae after PID caused by C. trachomatis and that 
caused by other etiologies seems to be similar (41). Genetic studies of individual 
immunopathogenetic factors have suggested that a single nucleotide polymorphism in 
inflammasome-associated NLRP3 is related to the severity of C. trachomatis infection (95). 
Screening for chlamydia infection and treatment can prevent PID, although, as mentioned in 
the section on prevention, some authors have questioned the cost-effectiveness of screening 
in the prevention of sequelae.  
3.2.2 Tubal factor infertility 
An estimated 5-15% of women of reproductive age are infertile, representing a major 
problem for more than 70 million women worldwide (15). According to the WHO, C. 
trachomatis postinfection damage of the fallopian tubes may cause 30–40% of cases of female 
infertility (99), the most common cause being PID.  
Multiple mechanisms can contribute to the development of this severe repercussion of C. 
trachomatis infection. Studies in the murine model have demonstrated that interstitial cells of 
Cajal (ICC), which form a dense network associated with the smooth muscle cells of the 
oviduct, are the source of the electrical pacemaker activity responsible for oviduct motility 
and egg transport, and that these cells are damaged by the inflammatory responses released 
by chlamydia infection. The destruction of the oviduct ICC networks might contribute to 
oviduct stasis and pseudo-obstruction, functional block of oocyte transport and retention of 
secretions, which could progress to fibrosis, tubal occlusion and finally infertility (32). 
Hydrosalpinx, a result of tubal obstruction, is present in about 30% of women with tubal 
factor infertility (TFI), and the fluid can reflux into the uterine cavity, inhibiting 
implantation of embryos in the endometrium. In addition, cystic fibrosis transmembrane 
conductance regulator (CFTR), an AMP-activated chloride channel that regulates epithelial 
electrolyte and fluid secretion and whose expression is elevated in the reproductive tract of 
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C. trachomatis-infected women, has been implicated in the pathogenesis of hydrosalpinx 
formation (2). Moreover, CFTR expression has another effect on fertility in the uterus, given 
that this substance plays a role in the regulation of the balance between the fluid volume in 
the endometrial mucous membrane during the estrous cycle, which is involved in blastocyst 
implantation. In the murine model, CFTR overexpression induced by cytokine release 
during C. trachomatis infection leads to abnormal fluid accumulation in uterus at diestrus 
and to a reduced implantation rate (43). 
In addition, individual genetic variations may play a major role in the immune response to 
C. trachomatis and in the pathogenesis of complications and sequelae. More specifically, 
functional polymorphisms in specific cytokine genes and other components of the host’s 
immune and proinflammatory response (IL-10, IL-12, TNF-, NRLP3...) are involved in the 
regulation of the immune response and contribute to the distinct manifestations of the 
disease and its outcomes (66). Lastly, the sequence identity shared between cHSP60 and 
human HSP60 (48.5%) has traditionally been considered to cause cross-reactivity and 
consequently autoimmunity, which could play a role in the pathogenesis of TFI. However, 
TFI has recently been associated with antibodies against cHSP60, but not against human 
HSP60, pointing to an infectious rather than an autoimmune inflammation and suggesting 
antibody testing as a supplement in TFI diagnosis (44). 
3.2.3 Ectopic pregnancy 
Approximately 1-2% of pregnancies are ectopic, and 97-98% occur in the Fallopian tubes, 
representing the main cause of maternal death in the first trimester of pregnancy (94). The 
risk of ectopic pregnancy is higher in women with Fallopian tube damage due to pelvic 
infections mainly by C. trachomatis or pelvic surgery, previous ectopic pregnancy, smoking 
and in vitro fertilization. Therefore, most of the above-mentioned etiopathogenic 
mechanisms of TFI can also cause an ectopic pregnancy.  
Tubal ectopic pregnancy is caused by a combination of factors that allow embryo retention 
in the Fallopian tube due to limitations in tubal transport and/or alterations in the tubal 
environment that favour early egg implantation. The Fallopian tubes in women with ectopic 
pregnancies show altered expression of prokineticin receptors (PROKRs), a molecule 
involved in the control of smooth muscle contractility. Through ligation of tubal Toll-like 
receptor 2 and activation of NFB (nuclear factor kappa-light-chain enhancer of activated B 
cells), C. trachomatis infection leads to increased tubal PROKR2, probably predisposing the 
tubal microenvironment to ectopic implantation (84). In addition, an increase in the 
expression of activins and inducible nitric oxide synthasa (iNOS) within the human Fallopian 
tube of patients with an ectopic pregnancy and antibodies against C. trachomatis has been 
observed, suggesting that these proteins may be involved in the microbial-mediated immune 
response that contributes to tubal damage and ectopic pregnancy (72). Nitric oxide production 
is considered to be part of the innate immune response (being bactericidal for intracellular 
pathogens, including C. trachomatis), but chronic chlamydia infections can lead to an excess of 
iNOS-derived nitric oxide, damaging tubal epithelial cells and possibly leading to an ectopic 
pregnancy (83). Lastly, the elafin molecule has anti-protease, anti-microbial, innate immune 
defence and anti-inflammatory properties and is found in various human mucosal membranes 
such as those of the female genital tract, and whose expression is increased in the Fallopian 
tubes of women with ectopic pregnancy. Elafin is also up-regulated in an in-vitro model in 
response to C. trachomatis infection (52). 
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3.2.4 Pregnancy outcomes    
C. trachomatis infection during pregnancy has been associated with adverse outcomes such 
as premature rupture of membranes (PRM), premature delivery, low birth-weight and 
miscarriage. However, the results of studies on this topic have often been distinct and even 
contradictory. Many of these publications included a small number of women and used 
inappropriate serological methods to distinguish between current and past infection.  
Recently, two large population-based studies (each with about 4000 women) have shed new 
light on the potential role of C. trachomatis in this context. A population-based retrospective 
cohort study carried out in Washington State (USA) using birth certificate data found that 
chlamydia-infected women had a higher risk of preterm delivery and PRM than a non-
infected control group (13). Premature delivery (<37 weeks) occurs in 9.6% of all births 
worldwide and can be due to multiple factors, with 30% being related to PRM (8). The 
mechanism through which chlamydia causes PRM is not well known, but could be 
produced through choriodecidual inflammation and chorioamnionitis generated through 
some of the above-mentioned etiopathogenetic mechanisms. Interestingly, this risk has been 
reported to decrease in successfully treated patients, given that the frequency of PRM was 
lower than in patients who were treated but who had either persistent or recurrent 
chlamydia infection at the end of pregnancy; furthermore, the risk was not significantly 
different to the risk in those without C. trachomatis detection in pregnancy (27). In the second 
population-based cohort study, a prospective and non-interventional analysis during 
pregnancy performed in Holland, C. trachomatis infection detected with NAATs was 
significantly associated with prematurity before 35 weeks of pregnancy, this risk being 
higher before 32 weeks (78). Of deliveries before 32 and 35 weeks of pregnancy, 14.9% and 
7.4%, respectively, were associated with C. trachomatis infection, suggesting that chlamydia 
contributes more to early than to late prematurity. In this study, pregnancy was shorter in 
chlamydia-positive women. Neither of these two population-based studies found that low 
birth weight (<2,500 g) or small-for-gestational-age neonates, or miscarriage were associated 
with maternal C. trachomatis infection.  
A recent Polish study found that the prevalence of C. trachomatis detected by NAATs and 
serology was higher in women who miscarried than in other pregnant women, suggesting 
that chlamydial infection can cause spontaneous pregnancy loss (97). However, studies 
designed to analyse the possible role of C. trachomatis in miscarriage are lacking and this 
issue continues to be controversial. Finally, postpartum endometritis is a common 
complication in C. trachomatis-infected women.  
3.2.5 Cervical neoplasia 
Cervical neoplasia is the second most common cancer in women worldwide, the main cause 
being persistent infection with high-risk HPV. However, only a small proportion of HPV 
infections are persistent and progress to cervical cancer, suggesting that co-factors may also 
be involved in its carcinogenesis. Some seroepidemiological studies have associated C. 
trachomatis with the development of cervical squamous cell carcinoma, and it has even been 
suggested that this association could be greater with specific serotypes (G, I, D and B) (6,65). 
The results of two large (8441 women), multinational, clinical trials that evaluated the safety 
and efficacy of an HPV vaccine suggested that C. trachomatis is an independent, but 
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moderate, co-factor for the development of cervical neoplasia. In addition, C. trachomatis 
seems to be involved only in the early stages of cervical carcinogenesis, as no increased risk 
associated with C. trachomatis was found for CIN-3 (55).  
The mechanisms causing this association are unknown. C. trachomatis modulates the host 
immune response and inhibits apoptosis, which could encourage the persistence of infected 
HPV cells. Moreover, C. trachomatis induces inflammation and cervical metaplasia, 
favouring the access and propagation of HPV, given that metaplastic cells are potential 
targets for HPV. Chlamydia infection may increase the access of HPV to the basal 
epithelium and increases HPV viral load (66). Therefore, some authors argue that 
associations between C. trachomatis and cervical premalignancy could be caused, in part, by 
an increased susceptibility to HPV infection (79). In contrast, new molecular evidence now 
suggests that chlamydial protease-like activity factor induces centrosome amplification, 
which may help to explain the role of chlamydia in cervical carcinogenesis (49).  
4. Microbiological diagnosis 
This section aims to outline the microbiological diagnostic methods most commonly used in 
C. trachomatis infection and to define the most appropriate samples for diagnosis in women. 
Diagnostic techniques, which are discussed in another chapter, will not be described in 
detail. A general consideration when approaching the diagnosis of an STI in the clinical 
setting is that other microorganisms that could cause coinfection should always be 
investigated. Consequently, other bacterial causes, such as N. gonorrhoeae and Trichomonas 
vaginalis, among others, must be excluded and a serum sample must be requested to 
investigate HIV, hepatitis B and C viruses and syphilis infection. Obviously, this practice is 
not applied in most screening programmes.  
Appropriate samples for C. trachomatis detection are cervical exudates, vaginal swabs and 
urine samples. Depending on the symptoms, conjunctival, pharyngeal and rectal exudates 
can also be obtained, as well as other samples in specific cases. Cervical exudates should be 
obtained by a gynecologist. Vaginal swabs can be self-collected or collected by a physician, 
with no differences in sensitivity or specificity (81). With urine sampling, it is essential to 
collect first-void urine, defined as the first 10-30mL of the urine, and for the patient not to 
have urinated for at least 2 hours previously. Self-collected vaginal swabs and first-void 
urine are samples that are widely accepted by women (12), and can be collected in-house 
and mailed to laboratories, thus facilitating epidemiological studies and screening 
programmes in asymptomatic women. In addition, urine allows samples to be grouped into 
pools and increases the cost-effectiveness of studies, with little reduction in sensitivity (77). 
A large German study, using 5 urine pools, obtained a negative predictive value of 98.1% for 
the pooling system (14). 
A wide variety of techniques are available for C. trachomatis detection. Cell culture, antigen-
based detection methods, such as direct fluorescent assay, immunochromatography and 
enzyme immunoassay, and nucleic acid hybridization tests have been widely used in 
clinical laboratories. Due to their lower sensitivity, all these techniques are being substituted 
by NAATs, which increase detection by 20-40% and are the currently recommended 
techniques. However, NAATs are expensive and their introduction for C. trachomatis 
detection may be difficult in some laboratories. The chlamydial load is lower in urine than in 
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vaginal swabs and is lower in the latter than in endocervical swabs (61). Therefore, vaginal 
swabs and urine should only be analysed through molecular amplification methods. These 
distinct chlamydial loads probably explain the lower sensitivity found by some authors 
when using first-void urine rather than vaginal or endocervical swabs (14), although this 
difference has not been found in all studies (75). The most recent NAATs use specific 
primers and probes that target two cryptic plasmid fragments or a fragment of the cryptic 
plasmid and another fragment of the ompA gene. These new NAATs are able to detect 
variants with deletions in the cryptic plasmid such as the new Swedish C. trachomatis variant 
(nvCT), first detected in 2006. The nvCT variant contains a 377-bp deletion in the cryptic 
plasmid that covers the single targets originally utilized in some commercial NAATs (74). 
The use of modern automatic nucleic acid extraction devices also helps to improve the 
sensitivity of techniques that perform manual extraction through lysis (69). 
Numerous point-of-care tests, based on immunological methods and providing rapid 
diagnosis have been designed for C. trachomatis detection. The sensitivity of these tests is 
currently considered to be inadequate, at around <50%, as is their specificity, given that 
most are based on lipopolysaccharide detection, which often presents cross-reaction with 
the lipopolysaccharide of Gram-negative bacteria, leading to the possibility of false-
positive results. Given this possibility, the development of a point-of-care tests that 
detects C. trachomatis with sufficient sensitivity (>90%) is currently a pressing need (48). 
Recently, new tests based on signal amplification systems have shown a higher sensitivity 
of around 80% (59). 
Serological methods are not useful in the diagnosis of uncomplicated C. trachomatis 
infection. The antibody profile generated in acute and chronic infection is not well known. 
Moreover, the serological response can been inconsistent or weak, since the infection is 
usually limited to the mucosal surface. Nevertheless, antibody detection is considered 
important in women with TFI, as serological evidence of past infection is associated with a 
significantly increased risk of women suffering TFI (4). Likewise, serological methods are 
useful in epidemiological studies (53). 
C. trachomatis typing can be performed through serotyping with monoclonal antibodies 
against the MOMP protein or genotyping of the ompA gene, whether through restriction 
fragment length polymorphism analysis or sequencing. Genotyping through sequencing is 
easier to implement in clinical laboratories and can be performed directly in the clinical 
sample, which explains its increasing use. This technique is allowing the worldwide 
distribution of distinct genotypes of C. trachomatis to be determined and its possible 
geographical features and temporal evolution to be compared (68). Other techniques 
allowing greater discrimination and differentiation among strains, such as MLST and 
VNTR, have been developed; these techniques will help to generate further insight into the 
natural history of the infection, thus enabling detailed clinical-epidemiological studies and 
aiding vaccine design.  
5. Treatment  
In addition to accurate diagnosis and appropriate antibiotic therapy, the management of 
uncomplicated C. trachomatis infection also requires counseling and treatment of the sexual 
partner(s), which reduces the possibility of reinfection of the original partner and infection 
of possible other partners, thus decreasing transmission within the community.  
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C. trachomatis is usually susceptible to tetracyclines, macrolides, fluoroquinolones, 
amoxicillin, rifampin and sulfonamides, among other antibiotics. With rare exceptions, such 
as rifampin, chlamydiae do not easily develop resistances to antibiotics and, because these 
microorganisms are obligate intracellular bacteria they are unlikely to acquire resistance 
genes from other bacteria through horizontal transmission (45). Although there are few 
studies of antimicrobial susceptibility in C. trachomatis, reports of isolates in patients with 
resistance strains are scarce, and in most of these reports, the isolates screened displayed 
characteristics of heterotypic resistance, affecting only a small part of the bacterial 
population. This type of resistance often disappears with the spread of the bacteria (80). 
However, heterotypic resistance could cause treatment failure in patients with high 
chlamydial load (46). A recent European study that included C. trachomatis isolates from all 
the urogenital serovars (D through K, n=45) found that all the isolates were susceptible to 
the antimicrobials tested: levofloxacin, erythromycin, doxycycline, clarithromycin, and 
azithromycin (33). Nevertheless, in India, decreased antibiotic susceptibility to azithromycin 
and doxycycline has been reported in 38% – a significant proportion – of the strains isolated 
in patients with recurrent infections (10). The advisability of monitoring the development of 
C. trachomatis resistance is hampered by the lack of standardized antimicrobial susceptibility 
tests, which currently require cell cultures.   
The standard treatment regimens for uncomplicated lower genital tract infections are one 
dose of azithromycin or two doses/day of doxycycline for 7 days (Table 2). Both regimens 
have shown an efficacy of >95% in the microbial cure of C. trachomatis (54), although 
compliance is lower with doxycycline. A single dose of azithromycin should be the 
treatment of choice in persons who may not be able to comply with longer treatment 
regimens. Other alternatives are erythromycin, which is associated with a higher rate of 
adverse effects, and ofloxacin and levofloxacin, which are more expensive. The treatment of 
HIV-infected women is similar. Treatment should be started as soon as possible, especially 
in women with urethritis/cervicitis with clear secretion and/or more then 5 leukocytes per 
field in the Gram stain, even when an etiologic diagnosis is unavailable. In these patients, 
the recommended empirical treatment includes an oral dose of azithromycin and an 
intramuscular dose of ceftriaxone to cover possible infection by – or coinfection with –N. 
gonorrhoeae. After starting treatment, patients should abstain from sexual contact for 7 days. 
 
Infection Antibiotic treatment
Urethritis/cervicitis 
Azithromycin 1 g po 1 dose
Doxycycline 100 mg/12h po 7 days
Lymphogranuloma
venereum 
Doxycycline 100 mg/12h po 21 days 
PID 
Cefoxitin 2 g/6h IV + doxycycline 100 mg/12h po
Clindamycin 900 mg/8h IV + gentamicin 1.5 mg/kg/8h IM/IV 
Pregnancy 
Azithromycin 1 g po 1 dose
Amoxicillin 500 mg/8h po 7 days
Ophthalmia  
neonatorum 
Erythromycin base or 
ethylsuccinate 50 mg/kg/day (4 doses) po 14 days
Infant pneumonia 
Erythromycin base or 
ethylsuccinate 50 mg/kg/day (4 doses) po 14 days
Table 2. Recommended regimens of antibiotic treatment in C. trachomatis infections 
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An indispensable component of treatment is partner management. This strategy is often 
difficult but it is essential to strongly advise patients to inform their sexual partners of their 
infection and for their partners to be examined. All sexual partners in the 60 days prior to 
symptom onset in the index case – or the last contact, if more than 60 days previously – must 
be diagnosed and treated. When attendance by sexual partners is highly unlikely, the index 
patient may be given the partner’s treatment and instructed in its use, a practice known as 
expedited partner therapy, which is easier if azithromycin is used. Lack of partner 
management is usually the most frequent cause of reinfection, and expedited partner 
therapy has been shown to be useful in ensuring partner treatment among men and in 
reducing repeat infections among women (20). 
A cure test is not routinely recommended if treatment of the index case has been adequate. 
This test is recommended in pregnancy (see below) and when there is doubt about 
treatment compliance, suspected reinfection or persistent symptoms. When a cure test is 
performed, NAATs should be used 3-5 weeks after the end of treatment. C. trachomatis 
nucleic acids can persist in cells for up to 3 weeks (23). Nevertheless, since reinfection is 
frequent in persons with previous C. trachomatis infection (47), a new test of C. trachomatis 
detection is recommended approximately 3 months after the end of treatment (23). 
In pregnancy, tetracyclines and fluoroquinolones are contraindicated. The recommended 
antibiotics are azithromycin, amoxicillin and erythromycin and the current first-line choice 
is a single oral dose of 1 g of azithromycin. Erythromycin produces a higher frequency of 
gastrointestinal adverse effects, requiring treatment withdrawal; moreover, in pregnant 
women, liver clearance of this drug is increased, which could reduce its plasma 
concentration, thus increasing the risk of treatment failure (66). Due to the lower 
effectiveness of antimicrobials in pregnancy, as well as the possible adverse effects on 
pregnancy course and the possibility of neonatal transmission, a cure test is recommended 
3-5 weeks after the end of treatment, as well as a further test at 3 months to exclude 
reinfection. In pregnant women with risk factors, such as those aged 25 years or with 
several sexual partners or a new sexual partner, an additional test should be performed in 
the third trimester of pregnancy (23). 
The treatments recommended in other situations are shown in table 2. Treatment of PID falls 
beyond the scope of this chapter. However, since C. trachomatis is one of the most common 
causes of PID, the etiology of PID is often polymicrobial and C. trachomatis detection in cases 
of PID is far from easy – especially without samples from the upper-genital tract – treatment 
of C. trachomatis should be covered in all patients with PID. 
Lastly, prophylaxis or specific treatment in the neonates of mothers with genital C. 
trachomatis infection is not recommended. These neonates should be monitored clinically to 
allow microbiological diagnosis and treatment if symptoms develop: up to one month 
should be allowed for the development of conjunctivitis, and up to 3 months for pneumonia.  
6. Prevention   
In addition to being easily treated with antibiotics, C. trachomatis infection is preventable. 
Because of the increasing incidence rates of this infection, the high percentage of the 
population that may have asymptomatic infection, and the severity of its potential sequelae, 
various control programs have been developed. The CDC in the USA recommend annual 
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chlamydia screening in all sexually active women aged ≤25 years and in older women with 
risk factors. Screening of all pregnant women is also recommended (23). In Europe, the 
ECDC have described four levels of intervention in C. trachomatis infection control (34): A) 
primary prevention: sexual health promotion and information; B) case management: 
guidelines for clinical and microbiological diagnosis, as well as for patient treatment, which 
includes contact tracing, and a system for case reporting; C) “opportunistic” testing:  
screening in asymptomatic persons from specified groups considered at risk to detect new 
cases, mainly in young persons and/or those with several sexual partners when attending 
health services for other reasons; and D) proactive systematic population-based screening, 
aimed at covering a substantial portion of a defined population to reduce the prevalence of 
infection. Although most European countries carry out the first two levels, fewer have 
experience and knowledge of the third and fourth levels. In this context, no consistent 
association between the economic resources of a country and the intensity of chlamydia 
control activities has been found (57). In their guidelines, the ECDC recognizes that there is 
insufficient epidemiological information for decision making and aims to obtain sufficient 
data between 2010-11. 
The increase in the last few years in the incidence rates of several STI such as C. trachomatis 
infection highlights the need to maintain and, if possible, intensify primary prevention 
through health education and safe sex campaigns, such as correct and consistent condom 
use. Information campaigns are essential to raise awareness of STI not only among young 
people but also among their parents and even the physicians involved in the management of 
these infections (96), since the stigma commonly associated with STI is usually a handicap to 
their management and to adherence to prevention programmes. Primary prevention of C. 
trachomatis infection through vaccination is not yet feasible. The complex antigen structure 
of this pathogen and still insufficient knowledge of the protective C. trachomatis antigens 
involved in the immune response have proven to be a barrier to the development of 
effective vaccines.  
Secondary prevention through opportunistic or systematic screening is still the most 
important intervention to limit the adverse effects of C. trachomatis infection on reproductive 
health (66). Screening for chlamydia in females aged <25 years has been described as one of 
the most beneficial and cost-effective preventive services that can be offered in medical 
practice (58), and has been considered as an A-rated recommended preventive service 
(strongest recommendation) (93). Screening of men has not been shown to be cost-efficient 
and, although this practice could prevent many infections in women, its impact on the 
burden of disease in women by testing young men or specific risk groups is controversial 
(38,50).  
Preventive strategies should focus especially on the young, because the incidence rates of 
infection are much higher in this population group and the increase observed in the last 
decade has affected mainly this age group, with little variation in other age groups (73). To 
comply with the objectives of public health programmes and reduce transmission among 
the population as far as possible, both wide acceptance among the target population and 
high coverage and regular uptake are essential (53). Unfortunately, screening coverage rates 
do not usually exceed 60%, partly due to lack of knowledge among some young women 
about the need for screening and the social stigma attached to STI (21,58). Publicity 
campaigns and strategies such as “Get Yourself Tested” (available at 
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http://www.gytnow.org) aim to improve these results and avoid the formation of core 
groups with high reinfection rates, such as sexually active adolescent girls or young men 
with a previous history of STI (7,36,66). The various screening modalities have contributed 
to the increase in the number of detected cases, without this increase representing a real rise 
in incidence, given that it essentially reveals previously undetected asymptomatic infections. 
Moreover, recent studies using mathematical models suggest that screening reduces the 
prevalence of infection (50,90).  
Opportunistic screenings aim to halt spread of infection and avoid its sequelae through 
detection of new cases in asymptomatically infected risk groups. The most common target 
groups are usually sexually active young persons, especially those with frequent changes of 
partner, pregnant women, women seeking pregnancy termination, and those undergoing 
instrumentation of the uterus. Partly due to differences in the local epidemiology and 
burden of disease, various policies and practices are underway in several countries such as 
the USA, England, Denmark, Estonia, Iceland, Latvia, Norway, and Sweden, although not 
all of these policies are nationwide and some are implemented in specific regions only 
(19,34,50,57). Women are usually more willing than men to undergo diagnostic tests for STI. 
For example, in Sweden, less than 30% of all persons tested for chlamydia are men (42). 
Since 2003 in Stockholm and currently in other Swedish counties, there is an opportunistic 
screening called “Chlamydia Monday”, because the campaign takes place annually one 
Monday in September. Every year, the number of chlamydia cases reported in Sweden is 
higher in September and October, since the opportunities of finding a new sexual partner 
and becoming infected increase in summer. During the campaign, massive media activity 
provides information and promotes condom use to prevent STI, and encourages people to 
get tested for chlamydia with the aim of recruiting young men in particular, who request 
testing less than women. “Chlamydia Monday” helps to raise awareness of the importance 
of STI among the public and is a cost-effective intervention to decrease the prevalence of 
chlamydia and its complications in Sweden, encouraging both men and women to seek 
testing (31). 
Systematic screening for chlamydia using the internet and self-sampling kits has been 
implemented in certain regions of The Netherlands among 16 to 29 year-olds and its results 
in terms of the impact on population prevalence and cost-effectiveness evaluation will allow 
the advisability of implementing a nationwide chlamydia screening programme to be 
assessed and the optimal strategy to be designed. The acceptability of this home-based 
screening was high, the response rate being 63% (40); however, increasing this response 
remains difficult. Innovative strategies such as those used in this programme that combine 
confidentiality, simplicity and perception of the benefit of screening could increase the 
participation achieved in opportunistic screenings.  
Knowledge of the impact of chlamydia screening on individuals and public health is limited 
(39,53). The health gains and cost-savings obtained by C. trachomatis screening programmes 
may have been overestimated, especially in epidemiological studies using serological 
techniques. The effect of screenings on reducing the risk of developing complications and 
sequelae has been analysed in some studies that have reached distinct conclusions; 
furthermore, comparison of these studies is difficult due to their various limitations, such as 
the study type and duration, the age groups analysed, and the multifactorial causes of the 
sequelae, among other factors. A large nonrandomized cohort study in female US Army 
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recruits found no differences in hospitalizations for PID among women who were screened 
compared with those who were not (26). Equally, a randomised study with 9-year follow-up 
in women aged 21-23 years performed in Denmark found no differences between screened 
and non-screened women in the rates of PID and long-term risk of reproductive 
complications as the outcome (5). In contrast, two randomized trials comparing chlamydia 
screening in young women with a control group not invited for testing found a 50% 
reduction in PID over the subsequent year (64,82). Finally, in another randomised trial, 
limited evidence was observed suggesting that screening for chlamydia reduces PID rates: 
10% of asymptomatic infected women not treated developed PID within a year, versus 2% 
of screened and treated women (63). Further studies evaluating the effectiveness of 
chlamydia screening are clearly needed. 
The risk of longer-term reproductive health consequences, such as infertility and ectopic 
pregnancy, is low after treatment of a single episode (62,66); however, as previously 
mentioned, the development of sequelae is influenced by the immunopathological changes 
produced after successive reinfections and by the length of the infection (39). Therefore, the 
optimal frequency for testing is currently estimated to be once a year or with each change of 
partner. In this context, tertiary prevention – i.e. accurate diagnosis and appropriate 
treatment – shortens the duration of infection, and, if partner management is included, 
prevents transmission chains and reinfections. 
In countries with a high prevalence of C. trachomatis infection, screening in pregnant or 
puerperal women increases infection control by including a substantial proportion of the 
target population. There is evidence of improved pregnancy and birth outcomes for 
pregnant women aged <25 years treated for chlamydia, and screening has been 
recommended (93). No studies have evaluated the effectiveness of screening in pregnant 
women aged >25 years old, but this practice could prevent adverse pregnancy outcomes 
and vertical infection. For these reasons, universal screening in pregnancy should be 
considered unless selective criteria can be validated (85). If the screening is performed at the 
beginning of pregnancy, there is a risk of not preventing possible reinfections, and if 
performed at the end, some of the complications of infection during pregnancy cannot be 
avoided. The CDC has recommended screening in all women at the first antenatal visit with 
rescreening in the third trimester in women aged ≤25 years and those who have a new or 
more than one sexual partner, as these are the women at highest risk. Women usually have 
little awareness of the transmission and effects of chlamydia before being tested, and the 
high acceptance of screening demonstrated in young women who have previously been 
informed of the sequels of this infection and its possible consequences on the health of their 
neonates will be essential to the uptake of chlamydia screening in future antenatal screening 
strategies (11). 
In summary, most chlamydia infections are undetected and therefore the potential 
complications and sequels that can arise are not prevented. In the next few years, 
improvement in screening programs due to the knowledge currently being gained will 
probably enhance not only individual benefit, but also the impact on public health.  
7. Conclusion 
C. trachomatis genital infection is an increasing public health problem worldwide and has 
major adverse effects on women’s reproductive health and in pregnancy. This infection may 
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go unnoticed in up to 75% of infected women. The development of molecular amplification 
techniques in the last few years has increased the sensitivity and specificity of the detection 
of this intracellular bacterium. Infection is easily treated with antibiotics, while single-dose 
therapy improves adherence. An essential part of treatment is contact management. 
However, the most effective weapon is prevention. The adoption of the optimal preventive 
measures for each country is helped by better knowledge of the incidence, prevalence and 
impact of this infection. National health systems should make every effort to improve 
surveillance and to provide information on this infection, its potential consequences and the 
possibilities of prevention to the public. Special emphasis should be placed on young 
persons and on the core groups that are least likely to follow these preventive measures. 
Prevention can be enhanced through screening, which is especially important in pregnant 
women to reduce complications in both the pregnancy and the neonate. Despite the 
progress made in the last few years in the knowledge of etiopathogenesis, diagnosis, 
treatment and prevention of C. trachomatis, further research is required to reduce the burden 
of this infection.  
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